妇科肿瘤患者微创子宫切除术后阿片类药物使用情况
前瞻性队列研究纳入118例计划行微创子宫切除术的妇科肿瘤患者,108例完成随访。出院后中位阿片类药物用量为10片(75 MME),33.33%患者出院后未使用阿片类药物,而中位处方量为30片。住院期间阿片类药物使用量高于中位数与出院后使用量高于中位数风险增加相关(RR 2.31,95% CI 1.38-3.87)。
要点
- 出院后中位阿片类药物用量为10片(75 MME),但中位处方量为30片,存在过度处方。
- 33.33%的患者出院后未使用任何阿片类药物。
- 住院期间阿片类药物使用量高于中位数者,出院后使用量高于中位数的风险增加(RR 2.31,95% CI 1.38-3.87)。
核心结论
- 在该队列中,阿片类药物处方量相对于实际使用量存在过度。
- 住院期间阿片类药物使用是出院后阿片类药物使用的最强预测因素。
- 更严格且个体化的阿片类药物处方实践可能有助于减少阿片类药物误用和转移。
研究设计与样本
- 前瞻性队列研究,在单一机构招募计划行微创子宫切除术的妇科肿瘤患者。
- 共118例符合条件女性接受微创子宫切除术,其中108例在两个随访时间点均有完整数据。
- 通过病历回顾和术后1-2周及4-6周随访调查评估术后阿片类药物使用情况,阿片类药物转换为口服吗啡毫克当量(MME)进行标准化。
主要发现
- 恶性肿瘤占79%,其中71%为子宫内膜癌;大多数手术为腹腔镜(73%)。
- 中位住院时间为1晚(IQR 1-1),住院期间接受中位30.75 MME(IQR 7.5-52.5 MME),23例女性(21.3%)住院期间未使用阿片类药物。
- 在1-2周随访时,中位使用量为6片5 mg羟考酮,即45 MME(IQR 0-15.5片)。
- 完成随访后,出院后中位使用量为10片,即75 MME(IQR 0-22.5片),36例参与者(33.33%)出院后未使用阿片类药物。
- 中位处方量为30片(范围10-60);多变量分析显示,住院期间阿片类药物使用量高于中位数与出院后阿片类药物使用量高于中位数的风险增加相关(RR 2.31,95% CI 1.38-3.87)。
临床怎么用
- 作者认为,更严格且个体化的阿片类药物处方实践可能有助于减少阿片类药物误用和转移。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To quantify, and identify predictors of, post-discharge opioid use in gynecologic oncology patients undergoing minimally invasive hysterectomy (MIH). METHODS: For this prospective cohort study, gynecologic oncology patients planning to undergo MIH were recruited at a single institution. Post-operative opioid usage was evaluated via chart review and surveys at 1-2-week and 4-6-week post-operative visits. Opioids are converted to oral morphine milligram equivalents (MME) for standardization. Descriptive statistics and modified Poisson regression were used to quantify opioid requirements and evaluate predictors of post-discharge opioid use respectively. RESULTS: One hundred eighteen eligible women underwent MIH. Of these, 108 had complete data at both follow-up timepoints. Malignancy was present in 79% of cases, 71% of which were endometrial cancer. Most surgeries were laparoscopic (73%). Median hospital stay was 1 night (IQR 1-1). Inpatients received a median of 30.75 MME (IQR 7.5-52.5 MME). Twenty-three women (21.3%) used no opioids while inpatient. At the 1-2-week follow-up median usage was 6 pills of 5 mg oxycodone, or 45 MME (IQR 0-15.5 pills). After complete follow-up, median post-discharge usage was 10 pills, or 75 MME (IQR 0-22.5 pills) and 36 participants (33.33%) used no opioids after hospital discharge. The median prescription was for 30 pills (range 10-60). Above median inpatient opioid use was associated with an increased risk of above median opioid usage after hospital discharge (RR 2.31, 95% CI 1.38-3.87) on multivariable analysis. CONCLUSIONS: In this cohort, opioids were overprescribed relative to use. Inpatient use was the strongest predictor of post-discharge opioid use. More restrictive, and personalized, opioid prescribing practices may be a pathway to reduce opioid misuse and diversion. PRéCIS: Opioids were overprescribed by a factor of three to gynecologic oncology patients, whose inpatient opioid requirement predicted post-discharge opioid needs after minimally invasive hysterectomy.
引用
- Weston E, Raker C, Huang D, et al. Opioid use after minimally invasive hysterectomy in gynecologic oncology patients. Gynecol Oncol. 2019. PMID: 31405609. doi:10.1016/j.ygyno.2019.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。